Company news

Voyager Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

October 29, 2023

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

August 6, 2023

Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results

August 2, 2023

Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast

July 26, 2023

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

July 9, 2023

Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting

May 17, 2023

Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results

May 8, 2023

Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors

May 8, 2023

Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 1, 2023

Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast

May 1, 2023

Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer’s Disease and GBA1 Gene Therapy Program for Parkinson’s Disease at the AD/PD™ Conference

March 27, 2023

Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

March 6, 2023

Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets

March 5, 2023

Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast

February 27, 2023

Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors

December 13, 2022

Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results

November 7, 2022

Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

October 31, 2022

Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

October 10, 2022

Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target

October 3, 2022

Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy

October 2, 2022

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs

September 6, 2022

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

August 3, 2022

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

August 2, 2022

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors

July 27, 2022

Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs

May 18, 2022

Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results

May 3, 2022

Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting

May 2, 2022

Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer

March 21, 2022

Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs

March 7, 2022

Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee

February 2, 2022

Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting

November 18, 2021

Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results

November 1, 2021

Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy

October 19, 2021

Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs

October 5, 2021

Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies

August 8, 2021

Voyager Therapeutics Announces Strategic Shift and Leadership Transitions

May 18, 2021

Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates

May 10, 2021

Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates

May 9, 2021

Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting

April 27, 2021

Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease

April 25, 2021

Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates

February 24, 2021

Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference

February 17, 2021

Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates

November 8, 2020

Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program

October 11, 2020

Voyager Therapeutics Appoints Nancy Vitale to its Board of Directors

September 14, 2020

Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer

September 13, 2020

Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates

August 9, 2020

Voyager Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates

May 5, 2020

Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2020 Annual Meeting

April 28, 2020

Voyager Therapeutics Provides Update on the RESTORE-1 Parkinson’s Disease Trial

April 2, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.